{"pmid":32479664,"title":"A Case Series of MGUS and COVID-19.","text":["A Case Series of MGUS and COVID-19.","Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre-malignant clonal plasma cell disorder, with 25 to 30% life-long risk of progression to multiple myeloma (MM).(1) It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis, and acquired angioedema.(2) Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS.(3,4).","Br J Haematol","Gonzalez-Lugo, Jesus D","Bachier-Rodriguez, Lizamarie","Goldfinger, Mendel","Shastri, Aditi","Sica, R Alejandro","Gritsman, Kira","Mehta, Vikas","Kabarriti, Rafi","Goel, Sanjay","Verma, Amit","Braunschweig, Ira","Kornblum, Noah","Mantzaris, Ioannis","32479664"],"abstract":["Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre-malignant clonal plasma cell disorder, with 25 to 30% life-long risk of progression to multiple myeloma (MM).(1) It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis, and acquired angioedema.(2) Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS.(3,4)."],"journal":"Br J Haematol","authors":["Gonzalez-Lugo, Jesus D","Bachier-Rodriguez, Lizamarie","Goldfinger, Mendel","Shastri, Aditi","Sica, R Alejandro","Gritsman, Kira","Mehta, Vikas","Kabarriti, Rafi","Goel, Sanjay","Verma, Amit","Braunschweig, Ira","Kornblum, Noah","Mantzaris, Ioannis"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479664","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjh.16906","topics":["Case Report"],"weight":1,"_version_":1668437835199283201,"score":9.490897,"similar":[{"pmid":32361703,"title":"Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report.","text":["Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report.","During the COVID-19 pandemic, we had a 25 years old male case without any underlying disease or history of autoimmune disease in COVID-19 Clinic, Isfahan, Iran. He presented with arthralgia and weakness so we started COVID-19 therapeutic regimen. In his hospitalization, creatinine increases and abnormalities in random urine sediment was seen. Methylprednisolone and cyclophosphamide were prescribed due to suspected glomerulonephritis. After renal biopsy the diagnose was confirmed as crescentic proliferative glomerulonephritis. The patient also, underwent plasmapheresis and intravenous immunoglobulin injection. He was discharged healthy without development of new pulmonary symptoms despite immunosuppressive treatment.","Iran J Kidney Dis","Moeinzadeh, Firouzeh","Dezfouli, Majid","Naimi, Azar","Shahidi, Shahrzad","Moradi, Hazhir","32361703"],"abstract":["During the COVID-19 pandemic, we had a 25 years old male case without any underlying disease or history of autoimmune disease in COVID-19 Clinic, Isfahan, Iran. He presented with arthralgia and weakness so we started COVID-19 therapeutic regimen. In his hospitalization, creatinine increases and abnormalities in random urine sediment was seen. Methylprednisolone and cyclophosphamide were prescribed due to suspected glomerulonephritis. After renal biopsy the diagnose was confirmed as crescentic proliferative glomerulonephritis. The patient also, underwent plasmapheresis and intravenous immunoglobulin injection. He was discharged healthy without development of new pulmonary symptoms despite immunosuppressive treatment."],"journal":"Iran J Kidney Dis","authors":["Moeinzadeh, Firouzeh","Dezfouli, Majid","Naimi, Azar","Shahidi, Shahrzad","Moradi, Hazhir"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361703","source":"PubMed","week":"202019|May 04 - May 10","locations":["Isfahan","Iran"],"countries":["Iran, Islamic Republic of"],"countries_codes":["IRN|Iran, Islamic Republic of"],"e_drugs":["Creatinine","Cyclophosphamide","Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666138495570149379,"score":83.41138},{"pmid":32306290,"pmcid":"PMC7165253","title":"Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report.","text":["Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report.","The outbreak of 2019 novel coronavirus disease (COVID-19) began since early December 2019, and has been declared as a public health emergency by the World Health Organization. Due to the hypercoagulable state, blood stasis and endothelial injury, severe patients with COVID-19 are at high risk for thrombosis. We report a case of very severe COVID-19 complicated with venous thrombosis and arteriosclerosis obliterans of lower extremities. Risk stratification for deep vein thrombosis and peripheral arterial disease are of vital importance for the prognosis of COVID-19.","J Thromb Thrombolysis","Zhou, Bo","She, Jianqing","Wang, Yadan","Ma, Xiancang","32306290"],"abstract":["The outbreak of 2019 novel coronavirus disease (COVID-19) began since early December 2019, and has been declared as a public health emergency by the World Health Organization. Due to the hypercoagulable state, blood stasis and endothelial injury, severe patients with COVID-19 are at high risk for thrombosis. We report a case of very severe COVID-19 complicated with venous thrombosis and arteriosclerosis obliterans of lower extremities. Risk stratification for deep vein thrombosis and peripheral arterial disease are of vital importance for the prognosis of COVID-19."],"journal":"J Thromb Thrombolysis","authors":["Zhou, Bo","She, Jianqing","Wang, Yadan","Ma, Xiancang"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306290","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s11239-020-02084-w","keywords":["2019 novel coronavirus disease","arteriosclerosis obliterans","rhabdomyolysis","type 2 diabetes","venous thrombosis"],"topics":["Case Report"],"weight":1,"_version_":1666138493351362561,"score":83.07643},{"pmid":32419710,"pmcid":"PMC7224655","title":"Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.","text":["Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.","*COVID-19 infection is associated with hypercoagulability and a prothrombotic state.*Little is understood about the prevalence of venous thromboembolism in mild disease.*We present a case of mild COVID-19 complicated by extensive deep venous thrombosis.","Thromb Res","Nauka, Peter C","Oran, Erick","Chekuri, Sweta","32419710"],"abstract":["*COVID-19 infection is associated with hypercoagulability and a prothrombotic state.*Little is understood about the prevalence of venous thromboembolism in mild disease.*We present a case of mild COVID-19 complicated by extensive deep venous thrombosis."],"journal":"Thromb Res","authors":["Nauka, Peter C","Oran, Erick","Chekuri, Sweta"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419710","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.thromres.2020.05.015","topics":["Case Report"],"weight":1,"_version_":1667159284436172802,"score":81.07849},{"pmid":32500936,"title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.","text":["Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.","Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor Tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: all were of male gender, with a mean age of 55.5+/-8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75+/-2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days respectively; in both patient a significant increase of total lymphocyte count was observed. In conclusion KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19 associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.","Transpl Infect Dis","Mella, Alberto","Mingozzi, Silvia","Gallo, Ester","Lavacca, Antonio","Rossetti, Maura Maria","Clari, Roberta","Randone, Olga","Maffei, Stefano","Salomone, Mario","Imperiale, Daniele","Biancone, Luigi","32500936"],"abstract":["Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor Tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: all were of male gender, with a mean age of 55.5+/-8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75+/-2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days respectively; in both patient a significant increase of total lymphocyte count was observed. In conclusion KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19 associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population."],"journal":"Transpl Infect Dis","authors":["Mella, Alberto","Mingozzi, Silvia","Gallo, Ester","Lavacca, Antonio","Rossetti, Maura Maria","Clari, Roberta","Randone, Olga","Maffei, Stefano","Salomone, Mario","Imperiale, Daniele","Biancone, Luigi"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500936","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13348","e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1668804508723970048,"score":81.006386},{"pmid":32399449,"pmcid":"PMC7213837","title":"Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","text":["Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage.","Eur J Case Rep Intern Med","Poggiali, Erika","Bastoni, Davide","Ioannilli, Eva","Vercelli, Andrea","Magnacavallo, Andrea","32399449"],"abstract":["Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage."],"journal":"Eur J Case Rep Intern Med","authors":["Poggiali, Erika","Bastoni, Davide","Ioannilli, Eva","Vercelli, Andrea","Magnacavallo, Andrea"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399449","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.12890/2020_001646","keywords":["covid-19 pneumonia","deep vein thrombosis","heparin","pulmonary embolism","venous thromboembolism"],"locations":["Pneumonia"],"e_drugs":["Heparin"],"topics":["Case Report"],"weight":1,"_version_":1666714494762483713,"score":78.837944}]}